INSM · Insmed Incorporated

NASDAQ-100 #88 · Nasdaq

Risiko 8/10 · Binary Biotech Catalyst Risk · $104.13 ▼ 0.57%

Kennzahlen

• Price $104.13
• Market cap $22.6B
• P/E (ttm) n/a
• Div yield none
• 52-wk range $90.39 – $212.75
• Index rank — / #88

Wichtigste Risiken

• Brensocatib commercial ramp uncertainty (PAD/bronchiectasis) (Revenue outlook) — EXTREME
• Clinical trial failure in pipeline assets (R&D investment) — EXTREME
• Reimbursement and pricing pressure from payers (Net revenue per patient) — HIGH
• Cash burn ahead of full profitability (Balance sheet) — HIGH

Fazit

Rare-disease biotech commercializing brensocatib; down ~51% from 52-week high as launch execution is scrutinized, with no P/E and binary pipeline risk.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.